Levels of F2-isoprostanes in systemic sclerosis: Correlation with clinical features

Rheumatology

Volumn 45, Issue 3, 2006, Pages 314-320

  Volpe, A ^a   Biasi, D ^a   Caramaschi, Paola ^a,b   Mantovani, W ^a   Bambara, L M ^a   Canestrini, S ^a   Ferrari, M ^a   Poli, G ^a   Degan, M ^a   Carletto, A ^a   Pieropan, S ^a   Minuz, P ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Dipartimento di Medicina Clinica e Sperimentale   (Italy)

Author keywords

F2 isoprostanes; Oxidative stress; Systemic sclerosis

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; AUTOANTIBODY; CREATININE; CYCLOPHOSPHAMIDE; FREE RADICAL; HISTAMINE H2 RECEPTOR ANTAGONIST; PREDNISOLONE; VASODILATOR AGENT; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE URINE LEVEL; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HEART DISEASE; HUMAN; HUMAN CELL; LIPID PEROXIDATION; LOW DRUG DOSE; LUNG DISEASE; MALE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROSTAGLANDIN URINE LEVEL; SCLERODERMA; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; ANGIOSCOPY; CAPILLARY; EVALUATION; HOSPITALIZATION; MIDDLE AGED; NAIL; PATHOLOGY; PATHOPHYSIOLOGY; URINE; VASCULARIZATION;

ADULT; AGED; BIOLOGICAL MARKERS; CAPILLARIES; DISEASE PROGRESSION; F2-ISOPROSTANES; FEMALE; HUMANS; LUNG DISEASES; MALE; MICROSCOPIC ANGIOSCOPY; MIDDLE AGED; NAILS; OXIDATIVE STRESS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; VON WILLEBRAND FACTOR;

EID: 33644865459     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei151     Document Type: Article

References (39)

1. Derk CT, Jimenez SA. Systemic sclerosis: Current view of its pathogenesis. Autoimmun Rev 2003;2:181-91.
2. Marasini B, Cugno M, Bassani C, Stanzoni M, Bottasso B, Agostoni A. Tissue-type plasminogen activator and Von Willebrand Factor plasma levels as marker of endothelial involvement in patients with Raynaud's phenomenon. Int Microcirc Clin Exp 1992; 11:375-82.
3. Murrell DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 1993;28:78-85.
4. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985;312:159-63.
5. Lau CS, O'Dowd A, Belch JJ. White blood cell activation in Raynaud's phenomenon of systemic sclerosis and vibration white finger. Ann Rheum Dis 1992;51:249-52.
6. Lau CS, Bridges AB, Muir A, Scott N, Bancroft A, Belch JJ. Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon. Br J Rheumatol 1992;31:375-80.
7. Sambo P, Jannino L, Candela M et al. Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 1999; 112:78-84.
8. Morita A, Minami H, Sakakibara N, Sato K, Tsuji T. Elevated plasma superoxide dismutase activity in patients with systemic sclerosis. J Dermatol Sci 1996;11:196-201.
9. Cotton SA, Emerit I. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 1999; 189:273-8.
10. Emerit I, Filipe P, Meunier P et al. Clastogenic activity in the plasma of scleroderma patients: A biomarker of oxidative stress. Dermatology 1997;194:140-6.
11. Solans R, Motta C, Sola R et al. Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: Evidence of free radical-mediated injury. Arthritis Rheum 2000;43:894-900.
12. Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: Implications for pathogenesis. J Exp Med 1997;185:71-9.
13. Morrow JD, Roberts LJ. The isoprostanes. Am J Resp Crit Care Med 2002;166:525-30.
14. Moore K, Roberts LJ. Measurement of lipid peroxidation. Free Radic Res 1998;28:659-71.
15. Stein CM, Tanner SB, Awad JA. Evidence of free radical-mediated injury (isoprostanes overproduction) in scleroderma. Arthritis Rheum 1996;39:1146-50.
16. Richelle M, Turini ME, Guidoux R, Tavazzi I, Metairon S, Fay LB. Urinary isoprostane excretion is not confounded by the lipid content of the diet. FEBS Lett 1999;459:259-62.
17. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990;87:9383-7.
18. Stein CM, Longmire AW, Minton TA, Roberts LJ, Pincus T, Morrow JD. Cyclosporine-induced alterations in renal function are not associated with lipid peroxidation. Transplantation 1994; 58:3865-8.
19. Cracowski JL, Marpeau C, Carpentier PH et al. Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. Arthritis Rheum 2001;44:1143-8.
20. 2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon. Arthritis Rheum 2002;46:1319-26.
21. 2α: Specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. Br J Clin Pharmacol 1996;42:15-19.
22. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
23. LeRoy EC, Black CM, Fleischmajer R et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5.
24. Akesson A, Fiori G, Krieg T, van den Hoogen FHJ, Seibold JR. Assessment of skin, joint, tendon and muscle involvement. Clin Exp Rheumatol 2002;21(Suppl 29):S5-S8.
25. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003;21(Suppl 29):S42-S46.
26. Valentini G, Della Rossa A, Bombardieri S et al. European multicentre study to define disease activity for systemic sclerosis. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8.
27. Cutolo M, Grassi W, Matucci Cerinic M. Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 2003; 48:3023-30.
28. Arcaro G, Fava C, Dagradi R et al. Acute hyperhomocysteinemia induces a reduction in arterial distensibility and compliance. J Hypertens 2004;22:775-81.
29. Riccieri V, Rinaldi T, Spadaro A et al. Interleukin-13 in systemic sclerosis: Relationship to nailfold capillaroscopy abnormalities. Clin Rheum 2003;22:102-6.
30. Valim V, Assis LSS, Simöes MFJ, Trevisani VFM, Puccinelli MLC, Andrade LEC. Correlation between serum E-selectin levels and panoramic nailfold capillaroscopy in systemic sclerosis. Braz J Med Biol Res 2004;37:1423-7.
31. Bryan C, Howard Y, Brennan P, Black CM, Silman A. Survival following the onset of scleroderma: Results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996;35:1122-6.
32. Matucci-Cerinic M, D'Angelo S, Denton CP, Vlachoyannopoulos P, Silver R. Assessment of lung involvement. Clin Exp Rheumatol 2003; 21(Suppl 29):S19-S23.
33. Groen H, Wichers G, ter Borg EJ, van der Mark TW, Vouda AA, Kallemberg CG. Pulmonary diffusing capacity disturbances are related to nailfold capillary changes in patients with Raynaud's phenomenon with and without an underlying connective tissue disease. Am J Med 1990;89:34-41.
34. Minuz P, Patrignani P, Gaino S et al. Determinants of platelet activation in human essential hypertension. Hypertension 2004; 43:64-70.
35. Greaves M, Malia RG, Milford Ward A et al. Elevated von Willebrand factor antigen in systemic sclerosis: Relationship to visceral disease. Br J Rheumatol 1988;27:281-5.
36. Blann AD, Sheeran TP, Emery P. von Willebrand factor: Increased levels are related to poor prognosis in systemic sclerosis and not to tissue antibodies. Br J Biomed Sci 1997;54:5-9.
37. 2α as a risk marker in patients with coronary heart disease. A matched case-control study. Circulation 2004;190:843-8.
38. 2α in rabbit lung in situ. Am J Physiol 1992;263:H660-H663.
39. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005;25:279-86.